LEVOCET -M Tablet Film-Coated Tablet Kenia - englanti - Pharmacy and Poisons Board

levocet -m tablet film-coated tablet

dawa limited p.o box 16633-00620 - levocetirizine hydrochloride and montelukast… - film-coated tablet - each film coated tablet contains:levocetirizine… - montelukast combinations

L-Histasin 5mg Film-Coated Tablets Malta - englanti - Medicines Authority

l-histasin 5mg film-coated tablets

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - levocetirizine dihydrochloride - coated tablet - levocetirizine dihydrochloride 5 mg - antihistamines for systemic use

Cetirizine Chefaro, 10mg, film-coated Tablets Malta - englanti - Medicines Authority

cetirizine chefaro, 10mg, film-coated tablets

chefaro ireland dac the sharp building, hogan place, dublin 2,, ireland - cetirizine hydrochloride - film-coated tablet - cetirizine hydrochloride 10 mg - antihistamines for systemic use

SITAGLIPTIN SANDOZ PHARMA sitagliptin (as hydrochloride monohydrate) 25 mg film-coated tablet blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

sitagliptin sandoz pharma sitagliptin (as hydrochloride monohydrate) 25 mg film-coated tablet blister pack

sandoz pty ltd - sitagliptin hydrochloride monohydrate, quantity: 28.34 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; sodium starch glycollate type a; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sitagliptin sandoz pharma is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: ? monotherapy when metformin is considered inappropriate due to intolerance; or ? in combination with other anti-hyperglycaemic agents, including insulin. [see sections 5.1 pharmacodynamic properties ? clinical trials and 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

JANTRA sitagliptin 50 mg film-coated tablet bottle Australia - englanti - Department of Health (Therapeutic Goods Administration)

jantra sitagliptin 50 mg film-coated tablet bottle

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 54.5 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; povidone; sodium stearylfumarate; croscarmellose sodium; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - jantra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

JANTRA sitagliptin 100 mg film-coated tablet bottle Australia - englanti - Department of Health (Therapeutic Goods Administration)

jantra sitagliptin 100 mg film-coated tablet bottle

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 109 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; croscarmellose sodium; povidone; sodium stearylfumarate; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - jantra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

JANTRA sitagliptin 100 mg film-coated tablet blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

jantra sitagliptin 100 mg film-coated tablet blister pack

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 109 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; calcium hydrogen phosphate dihydrate; sodium stearylfumarate; povidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - jantra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

JANTRA sitagliptin 50 mg film-coated tablet blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

jantra sitagliptin 50 mg film-coated tablet blister pack

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 54.5 mg (equivalent: sitagliptin, qty 50 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; povidone; microcrystalline cellulose; sodium stearylfumarate; croscarmellose sodium; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - jantra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

JANTRA sitagliptin 25 mg film-coated tablet bottle Australia - englanti - Department of Health (Therapeutic Goods Administration)

jantra sitagliptin 25 mg film-coated tablet bottle

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 27.25 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium stearylfumarate; croscarmellose sodium; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; povidone; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - jantra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

JANTRA sitagliptin 25 mg film-coated tablet blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

jantra sitagliptin 25 mg film-coated tablet blister pack

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 27.25 mg (equivalent: sitagliptin, qty 25 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; croscarmellose sodium; magnesium stearate; sodium stearylfumarate; povidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - jantra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].